Valvular heart disease is a condition in which heart valves does not work properly. There are four types of the valves present in the heart namely; tricuspid, mitral, pulmonary and aortic valves. Heart valves comprise of tissue flaps that open and close with each heartbeat and ensure the right direction of blood flow. Due to infections, birth defects, and age-related changes, heart valves do not function properly, with some of the problems observed in valvular heart diseases including; stenosis, regurgitation, and atresia. MyoKardia, Inc. is in the process of developing MYK-461 as a myosin inhibitor for the treatment of valvular artery disease. Bayer AG is in the process of developing rivaroxaban as a factor IXa inhibitor for the treatment of the disease. Some of the companies having a pipeline of valvular heart disease include Heart Metabolics Limited, Bayer AG, MyoKardia, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.